Recent developments
Targeted oncology modalities
In thoracic oncology, combining obrixtamig with zocilurtatug pelitecan advances DLL3‑directed strategies in ES‑SCLC and NECs. A separate study pairs obrixtamig with pumitamig to test dual immune and anti‑angiogenic mechanisms. Ifinatamab deruxtecan received FDA Priority Review for ES‑SCLC. In gynecologic cancer, GSK’s mocertatug rezetecan showed high responses, and rinatabart sesutecan plus bevacizumab was tolerable.
Key approvals and trials
The EU approved pembrolizumab plus paclitaxel ± bevacizumab for PD‑L1 CPS≥1 platinum‑resistant ovarian cancer after 1–2 prior regimens. China approved Exdensur (depemokimab) for CRSwNP with twice‑yearly dosing. Merck initiated the pivotal MALBEC trial of MK‑8748 in neovascular AMD; Roche’s Elecsys NfL test gained CE mark to support blood‑based monitoring in RRMS.
Metabolic therapies and delivery
FDA approved Foundayo (orforglipron), a once‑daily oral small‑molecule GLP‑1 for chronic weight management. EMA allowed Wegovy injection controlled‑temperature delivery for up to 48 hours, easing last‑mile cold‑chain constraints. An indirect comparison reported greater weight loss and lower discontinuation for oral semaglutide 25 mg versus orforglipron.
Manufacturing and infrastructure
AGC Pharma Chemicals earned Best‑in‑Class recognition across four Small/Mid‑Sized API CDMO categories. At Chemspec Europe, Saltigo will present capabilities in high‑pressure hydrogenation, phosgenation, fluorination and flow chemistry for complex intermediates. SPIE agreed to acquire the BLOCK group to expand cleanroom EPC capacity as CELLforCURE evaluated a sale of its Les Ulis site.
Financing and partnerships
The EIB will lend €100 million to Orion Pharma for R&D, trials and equipment. GSK completed the acquisition of 35Pharma, adding an activin‑pathway program for pulmonary hypertension. Novo Nordisk entered a strategic partnership with OpenAI spanning discovery, manufacturing and supply chain.